Organon (OGN) Total Current Liabilities (2020 - 2026)
Organon (OGN) recorded quarterly Total Current Liabilities of $2.5 billion in Q1 2026, up 4.6% quarter-over-quarter from $2.4 billion in Q4 2025, and down 4.4% on a YoY basis from $2.6 billion in Q1 2025.
Organon (OGN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Organon's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $2.5 billion for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 4.4% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (down 4.4% YoY), while the FY2025 annual figure was $2.4 billion, down 12.07% from the prior year.
- Total Current Liabilities was $2.5 billion for Q1 2026 at Organon, up from $2.4 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.9 billion in Q4 2023 to a low of $2.3 billion in Q1 2022.
- Historically, Total Current Liabilities has averaged $2.6 billion across 5 years, with a median of $2.5 billion in 2022.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities fell 25.6% in 2022, then grew 16.16% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $2.5 billion in 2022, then gained by 16.16% to $2.9 billion in 2023, then retreated by 6.85% to $2.7 billion in 2024, then dropped by 12.07% to $2.4 billion in 2025, then grew by 4.6% to $2.5 billion in 2026.
- The last three Total Current Liabilities figures came in at $2.5 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | -30.24 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 2.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.50 Bn |
| Dec 31, 2025 | 2.39 Bn |
| Sep 30, 2025 | 2.68 Bn |
| Jun 30, 2025 | 2.80 Bn |
| Mar 31, 2025 | 2.62 Bn |
| Dec 31, 2024 | 2.72 Bn |
| Sep 30, 2024 | 2.79 Bn |
| Jun 30, 2024 | 2.76 Bn |
| Mar 31, 2024 | 2.55 Bn |
| Dec 31, 2023 | 2.92 Bn |
| Sep 30, 2023 | 2.49 Bn |
| Jun 30, 2023 | 2.39 Bn |
| Mar 31, 2023 | 2.35 Bn |
| Dec 31, 2022 | 2.51 Bn |
| Sep 30, 2022 | 2.33 Bn |
| Jun 30, 2022 | 2.40 Bn |
| Mar 31, 2022 | 2.31 Bn |
| Dec 31, 2021 | 2.60 Bn |
| Sep 30, 2021 | 3.13 Bn |
| Jun 30, 2021 | 2.98 Bn |